| Literature DB >> 33820786 |
Maxime Sasseville1,2,3, Annie LeBlanc3,4, Mylène Boucher3, Michèle Dugas3, Gisele Mbemba3, Jack Tchuente3, Maud-Christine Chouinard5, Marianne Beaulieu2,3, Nicolas Beaudet6,7, Becky Skidmore8, Pascale Cholette9, Christine Aspiros10, Alain Larouche11, Guylaine Chabot11, Marie-Pierre Gagnon2,3.
Abstract
OBJECTIVE: Determine the effectiveness of digital mental health interventions for individuals with a concomitant chronic disease.Entities:
Keywords: general medicine (see internal medicine); health informatics; mental health
Mesh:
Year: 2021 PMID: 33820786 PMCID: PMC8030477 DOI: 10.1136/bmjopen-2020-044437
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
PICO eligibility criteria
| Population (P) | Adults with any chronic disease (eg, diabetes, ischaemic heart diseases, cerebrovascular diseases, chronic obstructive pulmonary disease, asthma, hypertension, dyslipidaemia, arthritis/rheumatoid arthritis, chronic pain, cancer, chronic renal disease, inflammatory bowel diseases, mood disorders and attention deficit disorders). We will rely in the authors’ definition of chronic disease and presenting, or at risk of presenting, a concomitant mental health problem (eg, mood disorders, depression, anxiety, obsessive compulsive disorder, panic disorder and post-traumatic stress disorder). |
| Intervention (I) | Digital health technologies, including but not limited to: telemedicine/teleconsultation, patient portal, electronic health record, web-based/internet intervention or smartphone applications. |
| Comparator (C) | No intervention, usual care and any other (digital or non-digital) intervention. |
| Outcomes (O) | Prevalence of mental health problems; scores of depression, anxiety or other mental health problem; quality of life; specific clinical indicators (eg, glycated hemoglobin (HbA1c) for diabetes); patient satisfaction; impact on care utilisation (eg, emergency department (ED) visits, hospitalisation and outpatient consultations); and costs (for the individual and the health system). |
Figure 1PRISMA flow diagram of study inclusion process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Description of included reviews
| Author, year | Review design | No. of primary studies, design | No. of patients (pooled) | Type of chronic diseases | Type of digital technology interventions | Depression outcomes | Anxiety outcomes | Other mental health outcomes |
| Chronic disease cluster | ||||||||
| Beatty | SR | 24 | NR | Chronic physical diseases | Web-based/internet intervention, app, email and relemedicine/teleconsultation. | Improvement between groups comparison. | Improvement at 3 months and at 12 months. | NR |
| Charova | SR with MA | 11 | 1348 | Any chronic disease with comorbid MH disorder | Web-based/internet intervention. | DW 0.31; 95% CI 0.17 to 0.45; p<0.01. | NR | NR |
| Clari, 2020 | SR | 1 | 84 | COPD | Telemedicine/teleconsultation. | No difference between groups. | No difference between groups. | Qualitative data: |
| Eccleston, 2019 | SR with MA | 14 | 2012 | Chronic pain | Web-based/internet intervention, app and telemedicine/teleconsultation. | SMD=−0.26 (95% CI −0.87 to 0.36). | SMD=−0.48 (95% CI −1.22 to 0.27). | NR |
| Hedman, 2012 | SR with MA | 108 | NR | Any | Web-based/internet intervention. | MD=0.94 (95% CI 0.77 to 1.11) large effect size, within groups. | MD=1.12 (95% CI 0.61 to 1.62), large effect size. | NR |
| McCombie, 2015 | SR | 29 | 3935 | Chronic physical diseases | Web-based/internet intervention. | Improvement of depression scores (4/8). | Improvement (2/7). | NR |
| Mehta, 2018 | SR with MA | 25 | 3450 | Any | Web-based/internet intervention and email. | Improved depression symptoms with small to medium effect size. | Improved anxiety, similar effect size than usual care. | NR |
| Mikolasek, 2018 | SR with meta-analysis | 17 | 1855 | Chronic physical diseases | Web-based/internet intervention. | Active control: 2/7 showed superior effectiveness; 4/7 equal effectiveness; 1/7 inferior effectiveness. | Active control: 2/7 showed superior effectiveness; 4/7 equal effectiveness; 1/7 inferior effectiveness. | NR |
| Palacios, 2017 | SR | 7 | 1321 | Chronic physical diseases | Web-based/internet intervention, app, email and text message. | PHQ-9 score mean from 12 (post) to 8.4 (follow-up). | NR | NR |
| Paul, 2013 | SR | 36 | NR | Any chronic disease with comorbid MH disorder. | Web-based/internet intervention and online chat. | Improved depression in comparison between groups. | Improved anxiety in comparison with control. | Mixed results in psychosocial outcomes. |
| Toivonen, 2017 | SR | 16 | NR | Any | Web-based/internet intervention, email and online chat. | Improved depression symptoms with a small effect size. | Improved anxiety symptoms with a small effect size. | NR |
| van Beugen, 2014 | SR with MA | 23 | 2299 | Any | Web-based/internet intervention, app, email, text message and online chat. | SMD=0.21 (95% CI: 0.08 to 0.34). | SMD=0.17 (95% CI 0.01 to 0.32). | General distress: SMD=0.21 (95% CI 0.00 to 0.41). |
| Vugts, 2018 | SR with MA | 46 | NR | Chronic physical diseases | Web-based/internet intervention, email, text message, online chat and telemedicine/teleconsultation. | SMD=−0.18 (95% CI −0.28 to −0.07). | NR | NR |
| Cancer cluster | ||||||||
| Agboola, | SR | 20 | 3789 | Cancer | Web-based/internet, app, virtual reality, text message, online chat and telemedicine/teleconsultation. | Heterogeneous studies no pooling possible. | Improvement in anxiety symptoms (3/8). | NR |
| Bártolo, | SR | 8 | 1016 | Cancer | Web-based/internet, patient portal, app, email and telemedicine/teleconsultation. | Improvement in depression symptoms 3 weeks postinterventions. Small effect size. | NR | Improvement in global distress, small effect size. |
| Bouma, | SR | 16 | 2620 | Cancer | Web-based/internet intervention. | Improvement on depression symptoms (1/7) (between groups). | Improvement in anxiety symptoms (2/10). | Improvement on quality of life (3/11). |
| Chen, 2018 | SR with MA | 20 | 2190 | Cancer | Web-based/internet intervention and telemedicine/teleconsultation. | SMD=1.29 (95% CI 2.28 to 0.30). | SMD=0.09 (95% CI 0.22 to 0.04). | Distress: SMD = ¼ 0.25,(95% CI 0.40 to 0.10, p<0.001). |
| Forbes, 2019 | SR | 16 | 2446 | Cancer | Web-based/internet intervention, email and online chat. | Improvement of depression score within group. | NR | Psychological distress: effect size larger with ICBT compared with forum. |
| Fridriksdottir, 2017 | SR | 20 | NR | Cancer | Web-based/internet intervention and email. | Improvement in depression symptoms (2/10). | Improvement in anxiety symptoms (4/10). | Improvement on psychological distress (3/8). |
| Kim, 2015 | SR with MA | 37 | NR | Cancer | Web-based/internet intervention, email, text message, online chat and telemedicine/teleconsultation. | Hedges’ g=−0.169 (−0.282 to −0.055). | Hedges’ g=−0.293 (−0.465 to −0.122). | QOL: Hedges' g=−0.221 (−0.359 to −0.084). |
| Kim, 2017 | SR with MA | 19 | 2381 | Cancer | Web-based/internet intervention and telemedicine/teleconsultation. | d=−0.07, p=0.284 (post). | d=−0.2, p=0.132. | NR |
| Lin, 2020 | Mixed | 16 | 1053 | Cancer | Web-based/internet intervention, app, email and text message. | Improvement of depression scores (5/11). | Improvement of anxiety scores (5/11). | NR |
| McCaughan, 2017 | SR | 6 | 492 | Cancer | Web-based/internet intervention, patient portal, email and online chat. | SMD=−0.37 (95% CI −0.75 to 0.00). | Mean 0. 4 lower at end of intervention (95% CI 6.42 lower to 5.62 higher). | NR |
| Qan'ir, 2019 | SR with MA | 10 | 1124 | Cancer | Web-based/internet intervention, app and online chat. | Improvement of depression score (between group) (2/7). | Improvement of anxiety score (between group) (1/5). | NR |
| Ugalde, 2015 | SR | 4 | NR | Cancer | Web-based/internet intervention. | NR | NR | Improved self-efficacy for regulating negative mood. |
| Wang, 2020 | SR with MA | 7 | 1220 | Cancer | Web-based/internet intervention, app and email. | SMD=−0.58, 95% CI (−1.12 to –0.03), p=0.04) (between groups). | SMD=−1.03 (95% CI − 2.63 to 0.57) (between groups). | NR |
| Zeng, 2019 | SR with MA | 6 | NR | Cancer | Virtual reality. | WMD=−1.11 (Z-scores=1.05, p=0.29). | SMD=−3.03 (95% CI=−6.20 to 0.15)). | NR |
| Youth and children cluster | ||||||||
| Fisher, 2019 | SR with MA | 10 | 697 | Chronic pain | Web-based/internet intervention and app. | SMD 0.04 (95% CI −0.18 to 0.26). | SMD 0.53 (95% CI −0.63 to 1.68). | NR |
| Lopez-Rodriguez, 2020 | SR | 8 | 286 | Cancer | App and virtual reality. | Improved depression (3/3). | Improved anxiety (2/3). | NR |
| McGar, 2019 | SR | 22 | 1764 | Chronic physical diseases | Web-based/internet intervention. | Improved depression symptoms (3/7). | Improved anxiety (4/5) (post). | Improved PTSD symptoms (2/3) (post). |
| Tang, 2018 | SR with MA | 4 | 404 | Chronic pain | Web-based/internet intervention. | MD=0.23 (95% CI 0.03 to 0.43) (within group). | SMD=3.24 (95% CI 1.88 to 4.61) (within group). | NR |
| Mental health cluster | ||||||||
| Lewis, 2018 | SR with MA | 10 | 720 | PTSD | Web-based/internet intervention. | SMD=−0.61 (95% CI −1.17 to −0.05)) (between groups/post). | SMD=−0.67 (95% CI −0.98 to −0.36)(between groups/post). | PTSD |
| Mayo-Wilson, 2013 | SR with MA | 43 | 8403 | Anxiety | Web-based/internet intervention, email, text message and telemedicine/teleconsultation. | NR | SMD=0.79 (95% CI 0.62 to 0.96) (internet delivered). | NR |
| Olthuis, 2016 | SR with MA | 38 | 3214 | Anxiety | Web-based/internet intervention, app, email, and nline chat. | NR | *RR=3.75 (95% CI 2.51 to 5.60) (generalised anxiety). | NR |
| Wickersham, 2019 | SR | 5 | 653 | PTSD | App | NR | NR | No improvement in PTSD between groups when compared with usual care. |
CBT, cognitive–behavioural therapy; COPD, chronic obstructive pulmonary disease; dw, Cohen’s effect size; iCBT, internet-based cognitive behavior therapy; MA, meta-analysis; MH, mental health; NR, not reported; PHQ-9, Patient Health Questionnaire; PTSD, post-traumatic stress disorder; QOL, quality of life; RR, risk ratio; SMD, standardized mean difference; SR, systematic review; WMD, weighted mean difference.
Critical appraisal of the included reviews
| 1. Question and inclusion | 2. Protocol | 3. Study design | 4. Comprehensive search | 5. Study selection | 6. Data extraction | 7. Excluded studies justify | 8. Included studies details | 9. Risk of bias (RoB) | 10. Sources of funding | 11. Statistical methods | 12. Meta-analysis RoB | 13. Individual studies RoB | 14. Heterogeneity explanation | 15. Publication bias | 16. Conflict of interest | Overall confidence rating | |
| Agboola 2015 | N | PY | Y | PY | Y | Y | Y | PY | Y | N | N/A | N/A | Y | N | N/A | Y | Low |
| Bartolo 2019 | Y | Y | Y | Y | Y | Y | Y | Y | PY | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Beatty 2012 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | N | Moderate |
| Bouma 2019 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Charova 2015 | Y | Y | Y | Y | Y | Y | Y | Y | PY | N | Y | Y | Y | Y | Y | Y | Moderate |
| Chen 2018 | Y | PY | Y | Y | Y | Y | Y | Y | PY | N | Y | Y | Y | Y | Y | Y | Moderate |
| Clari 2020 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | High |
| Eccleston 2019 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| Fisher 2019 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| Forbes 2019 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | High |
| Fridriksdottir 2017 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Hedman 2012 | Y | N | Y | Y | Y | Y | Y | Y | PY | N | Y | Y | Y | Y | Y | Y | Low |
| Kim 2015 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Moderate |
| Kim 2017 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | N | Moderate |
| Lewis 2018 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| Lin 2020 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Lopez-Rodriguez 2020 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | Y | Y | High |
| Mayo-Wilson 2013 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| McCaughan 2017 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| McCombie 2015 | Y | N | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Low |
| McGar 2019 | Y | PY | Y | Y | Y | Y | Y | Y | PY | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Mehta 2019 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Moderate |
| Mikolasek 2018 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Olthuis 2016 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Moderate |
| Palacios 2017 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Paul 2013 | Y | PY | Y | PY | N/A | N/A | Y | Y | PY | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Qan'ir 2019 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Moderate |
| Tang 2018 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| Toivonen 2017 | Y | N | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | Low |
| Ugalde 2017 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | High |
| van Beugen 2014 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Moderate |
| Vaugts 2018 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| Wang 2020 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | High |
| Wickersham 2019 | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | N/A | N/A | Y | Y | N/A | Y | High |
| Zeng 2019 | Y | PY | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Moderate |
NA, not applicable; N, no; PY, partial yes; Y, Yes.
Figure 2Overall critical appraisal of the included studies using the AMSTAR 2 tool.
Studies reporting improvements classified by the type of digital technology used
| Chronic diseases cluster | Cancer cluster | Children and youth cluster | Mental health cluster | |||||||||
| Depression | Anxiety | Other | Depression | Anxiety | Other | Depression | Anxiety | Other | Depression | Anxiety | Other | |
| Web-based interventios | ||||||||||||
| Patient portal | ||||||||||||
| Smartphone application | ||||||||||||
| Virtual reality | ||||||||||||
| Text messae | ||||||||||||
| Online chat | ||||||||||||
| Telemedicine/teleconsultation | ||||||||||||